. 2022 Jan 17;35(4):e15303. doi: 10.1111/dth.15303
© 2022 The Authors. Dermatologic Therapy published by Wiley Periodicals LLC.
This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
FIGURE 1.
Study design OMA 150/300, omalizumab 150/300 mg; sc, subcutaneous